NCT07892937

Brief Summary

CIC101-02-LT is a long-term follow-up study of subjects treated with TRTP-101 and will evaluate the long-term safety and efficacy of TRTP-101.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at below P25 for all trials

Timeline
82mo left

Started Mar 2027

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 19, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 23, 2026

Completed
5 months until next milestone

Study Start

First participant enrolled

March 31, 2027

Expected
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2033

9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2033

Last Updated

October 23, 2026

Status Verified

October 1, 2026

Enrollment Period

6 years

First QC Date

October 19, 2026

Last Update Submit

October 19, 2026

Conditions

Atrophic Scar

Outcome Measures

Primary Outcomes (1)

  • Serious Adverse Event

    SAE will be collected

    Up to 5 years

Secondary Outcomes (1)

  • Mean percent change in atrophic scar volume

    6 (only Phase 1 participants), 12, 18 and 24 months

Other Outcomes (1)

  • Patient's Satisfaction

    6 (only Phase 1 participants), 12, 18 and 24 months

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults with Atrophic Scars Treated with TRTP-101 in Study CIC101-02

You may qualify if:

  • Received TRTP-101 in clinical trial CIC101-02
  • Provided written informed consent to participate in this study

You may not qualify if:

  • Judged to face significant health or safety risks by participating in this long-term follow-up study
  • Judged to be unable to continuously participate in or complete this long-term follow-up study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • JongHee Lee, MD

    Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

HyeJung Park, Director

CONTACT

82-70-4469-9115hjpark@cellincells.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 19, 2026

First Posted

October 23, 2026

Study Start (Estimated)

March 31, 2027

Primary Completion (Estimated)

March 31, 2033

Study Completion (Estimated)

December 31, 2033

Last Updated

October 23, 2026

Record last verified: 2026-10